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Abstract
Background: Chronic obstructive pulmonary disease (COPD) has been consistently associated with increased risk of lung
cancer. However, previous studies have had limited ability to determine whether the association is due to smoking.
Methodology/Principal Findings: The Environment And Genetics in Lung cancer Etiology (EAGLE) population-based case-
control study recruited 2100 cases and 2120 controls, of whom 1934 cases and 2108 controls reported about diagnosis of
chronic bronchitis, emphysema, COPD (chronic bronchitis and/or emphysema), or asthma more than 1 year before
enrollment. We estimated odds ratios (OR) and 95% confidence intervals (CI) using logistic regression. After adjustment for
smoking, other previous lung diseases, and study design variables, lung cancer risk was elevated among individuals with a
history of chronic bronchitis (OR=2.0, 95% CI=1.5–2.5), emphysema (OR=1.9, 95% CI=1.4–2.8), or COPD (OR=2.5, 95%
CI=2.0–3.1). Among current smokers, association between chronic bronchitis and lung cancer was strongest among lighter
smokers. Asthma was associated with a decreased risk of lung cancer in males (OR=0.48, 95% CI=0.30–0.78).
Conclusions/Significance: These results suggest that the associations of personal history of chronic bronchitis, emphysema,
and COPD with increased risk of lung cancer are not entirely due to smoking. Inflammatory processes may both contribute
to COPD and be important for lung carcinogenesis.
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Introduction
Every year, over 1 million people diefrom lung cancer worldwide
[1].Althoughcigarettesmoking istheprimary etiologicagent in85–
90% of all lung cancers [2], only 10–15% of active smokers develop
lung cancer [3]. In addition, lung cancer is the seventh most
common cause of cancer death worldwide in never smokers [4].
While risk factors suchasfamilyhistory oflung cancer, occupational
carcinogens,andradonaccount forsome increasedrisk,theetiology
of lung cancer in this population remains poorly understood [4].
Associations between nicotinic receptors and lung cancer from
genome-wide association studies [5–7] only account for a small
component of the increased risk, suggesting that additional factors
must be involved in lung carcinogenesis.
Chronic obstructive pulmonary disease (COPD) has been
suggested as a risk factor for lung cancer. COPD can be
exacerbated by pulmonary infections [8,9] that cause inflamma-
tion, which contributes to lung carcinogenesis [10], and carcino-
genesis in general [11], by generating reactive oxygen or nitrogen
species, increasing cellular proliferation, upregulating antiapopto-
tic pathways, and stimulating angiogenesis [10]. Infections may
also promote airway remodeling that could enhance carcinogen-
esis [12]. Although COPD is strongly and consistently associated
with lung cancer [13–16], the degree to which the association
between COPD and lung cancer is due to smoking or other factors
remains unclear [3]. Few studies have had appropriate data and
sufficient cases to evaluate COPD and lung cancer by histology
and time since diagnosis of previous COPD.
The Environment And Genetics in Lung cancer Etiology
population-based case-control study (EAGLE) was specifically
designed to evaluate comprehensively a variety of risk factors for
lung cancer. With over 2000 cases, EAGLE allows evaluation of
the association of COPD and lung cancer by smoking status,
histology, gender, and time since COPD diagnosis.
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The EAGLE study has previously been described [17]. In brief,
EAGLE is a large population-based study of 2100 consecutive
incident lung cancer cases and 2120 controls from the Lombardy
region of northern Italy. Cases were enrolled from 13 hospitals in
216 municipalities including 5 large cities (Milan, Monza, Brescia,
Pavia, and Varese). Healthy controls were randomly sampled from
the Regional Health Service database and frequency matched to
cases by age, sex, and area of residence. The participation rates
(number of subjects who agreed to participate/eligible subjects)
were 86.6% for cases and 72.4% for controls. Each participant
provided written informed consent. The study was approved by
the Institutional Review Board (IRB) of each participating hospital
and university in Italy and by the National Cancer Institute,
Bethesda, MD.
We defined COPD as reporting a diagnosis of chronic
bronchitis and/or emphysema. We chose not to include asthma
in the definition of COPD since asthma is not strongly associated
with smoking and often develops in childhood [18,19], whereas
chronic bronchitis and emphysema are strongly associated with
smoking, occur more commonly with increasing age, and often
occur together [20–22]. We included asthma separately since
historically it has been considered a component of COPD [23].
Participants were asked (in Italian) through a computer-assisted
personal interview (CAPI) ‘‘whether a doctor ever told you more
than one year ago that you had any of these conditions: chronic
bronchitis, emphysema, asthma’’ and ‘‘How old were you when
this condition was first diagnosed?’’ We evaluated chronic
bronchitis and emphysema both independently and jointly. We
calculated latency for each condition as the difference between
study age (age at first diagnosis of lung cancer or interview) and
age at first diagnosis of previous lung disease. Ten cases and four
controls who provided a date of previous chronic bronchitis,
emphysema, or asthma less than one year before study entry were
excluded, leaving 2091 cases and 2116 controls. Of these, 1934
(92.5%) cases and 2108 (99.6%) controls provided data on chronic
bronchitis, emphysema, or asthma. These percentages are similar
to the overall CAPI completion rates for cases (92.6%) and
controls (99.8%).
Lung cancer was diagnosed according to standard clinical
criteria with pathologic confirmation from surgery, biopsy, or
cytology samples in approximately 95% of cases. The remaining
cases were confirmed through clinical history and imaging [17].
Main analyses included all primary lung cancer cases regardless of
histological type. Histology-specific analyses were restricted to
adenocarcinoma, squamous cell carcinoma, large cell carcinoma,
or small cell carcinoma. Tumor histology was defined using the
WHO Histological Typing of Lung and Pleural Tumors (1999).
Weused unconditionalbinarylogisticregression tocalculateodds
ratios (ORs) and 95% confidence intervals (CIs) for the association
of chronic bronchitis, emphysema, COPD, and asthma with lung
cancer and polytomous logistic regression to calculate ORs and
95% CIs by histological type. All models included the design
variables (study age, gender, and region). Potential confounders,
including smoking (e.g., smoking intensity (average packs per day),
time since last smoking quit attempt and entry into EAGLE),
demographic/socioeconomic variables (e.g., education, marital
status), and other factors, were evaluated through backwards
modeling using chronic bronchitis as the main exposure. Since
the removal of continuous pack-years, emphysema, and pneumonia
changed the beta coefficient for chronic bronchitis by more than
10%, they were retained in the adjusted models. In accord with
several recent studies [24–26], we selected pack-years and smoking
intensity to adjust for smoking exposure; however, models using
other closely related smoking metrics (smoking duration; time since
quitting smoking; age at initiation of cigarette smoking; environ-
mental tobacco smoke in childhood, adulthood at work, or
adulthood at home; and other tobacco smoking) produced almost
identical results. Chronic bronchitis changed the beta coefficient for
emphysema by more than 10% and thus was included in
multivariate models where chronic bronchitis was not the main
effect or a component of the main effect (i.e., COPD).
Smoking, gender, and latency were evaluated as effect-measure
modifiers using likelihood ratio tests (LRTs) for interaction on the
multiplicative scale adjusted as described above. Differences in
ORs for separate histological types were evaluated with the Wald
test for homogeneity.
Results
Compared to controls, cases tended to be less educated, less
likely to be married or cohabitating, and more likely to be current
smokers [Table 1]. Among smokers, the mean smoking intensity
(average packs per day) was 1.1 (standard deviation (SD) =0.5)
among cases and 0.8 (SD=0.5) among controls, and the mean
pack-years was 48.6 (SD=27.9) among cases and 27.3 (SD=22.1)
among controls. Among cases, the mean age at diagnosis of
chronic bronchitis was 45.0 years (median =48, range =0–78) in
cases and 56.4 years (median =61, range =3–77) in controls (t-
test for difference in group means p-value ,0.001), of emphysema
was 54.2 years (median 57, range =6–77) in cases and 56.3 years
(median 58, range =18–78) in controls (t-test p-value =0.3), of
COPD was 46.4 years (median =50, range =0–78) in cases and
56.4 years (median =60, range =3–78) in controls (t-test p-value
,0.001), and of asthma was 39.1 years (median =44, range =0–
75) in cases and 41.6 years (median =49, range =1–77) in
controls (t-test p-value =0.5).
After adjustment for smoking and other factors, chronic
bronchitis, emphysema, and COPD were associated with an
approximately two-fold increased risk of lung cancer [Table 2].
Results were similar when restricted to individuals diagnosed with
chronic bronchitis, emphysema, or COPD at or above age 18
(data not shown). Evaluating chronic bronchitis and emphysema
as a combined variable, the OR for having both chronic bronchitis
and emphysema (2.5, 95% CI=1.6–4.0) was similar to the ORs
for having chronic bronchitis only (2.3, 95% CI=1.8–3.0) or
emphysema only (2.9, 95% CI=1.8–4.6). Given that the OR for
having both chronic bronchitis and emphysema was no stronger
than having chronic bronchitis or emphysema separately, chronic
bronchitis and emphysema were maintained as separate variables.
In a subset of cases with spirometry data available, self report-
based COPD was strongly associated spirometry-based COPD
[27] (OR=3.0, 95% CI=2.1–4.3).
Although gender did not modify the association of lung cancer
with chronic bronchitis, emphysema, or COPD (LRT p-values
=0.4, 0.3, 0.6, respectively), the OR for asthma among males was
0.48 (95% CI=0.30–0.78) and among females was 1.1 (95%
CI=0.57–2.3) (LRT p-value for interaction =0.03). Among men,
even the minimally adjusted OR suggested an inverse association,
which was substantially strengthened after accounting for chronic
bronchitis and emphysema, both of which increased the risk of
lung cancer [Table 2]. Among women there was no association
regardless of adjustment. Since only 48 women (23 cases) reported
asthma diagnosis, additional analyses focused on men with more
limited analyses in women.
The ORs for chronic bronchitis and asthma did not vary by
smoking status [Table 3]. We observed an increased risk with
COPD and Lung Cancer
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smoking cases had emphysema, limiting power to detect
differences by smoking status (LRT p-value=0.3). Similarly, the
strongest effect of COPD was seen in smokers, although the LRT
p-value was 0.4. Restricted to current smokers, the strength of the
association between chronic bronchitis and lung cancer decreased
with increasing pack-years, smoking intensity, and smoking
duration [Table 4] (LRT p-values for continuous pack-years and
smoking intensity ,0.001, smoking duration 0.02). The trends for
COPD were similar to those for chronic bronchitis. Emphysema
and asthma in males showed no clear pattern by pack-years,
smoking intensity, and smoking duration. There were too few
women with asthma for extended analyses by smoking status.
Risk of lung cancer increased with time since diagnosis of
chronic bronchitis (LRT p-value =0.002) and COPD (LRT p-
value =0.007) but did not consistently increase or decrease with
time since diagnosis of emphysema (LRT p-value =0.2) or asthma
among males (LRT p-value =0.9) [Table 5]. The asthma in males
was consistently associated with a decreased risk of lung cancer for
asthma diagnosed more than five years prior, however. Among
women, the OR for asthma diagnosed 1–5 years prior to lung
cancer or enrollment was 0.50 (95% CI=0.09–2.9) and for
asthma diagnosed .5 years prior was 1.7 (95% CI=0.75–4.0,
LRT p-value=0.4). The distribution of ever/never smoking, time
since last quit smoking, and family history of lung cancer varied
little by latency (data not shown). Although latency and age at
diagnosis are highly correlated, we also evaluated the association
of age at diagnosis of chronic bronchitis or COPD with risk of lung
cancer since the mean age at diagnosis of chronic bronchitis and
COPD differed for cases and controls. The age at diagnosis results
mirrored the latency results. Restricting to subjects with known
age at diagnosis, later age at diagnosis (and thus likely shorter
latency) was associated with decreased risk of lung cancer for both
chronic bronchitis (OR=0.95, 95% CI=0.93–0.97) and COPD
(OR=0.95, 95% CI=0.93–0.97).
The associations of lung cancer with chronic bronchitis,
emphysema, COPD, asthma in men, and asthma in women did
not vary by histology (Wald p-value =0.4, 0.4, 0.7, 0.6, 0.7,
respectively), although numbers were small for some histology
categories. We also stratified by high and low pack-years for
adenocarcinoma separately because this histologic subgroup
exhibits demographic, smoking-related [4,28], and molecular
[29,30] differences compared with other histologies. Among ever
smokers, the OR for chronic bronchitis was 1.8 (95% CI=0.91–
3.7) for adenocarcinoma and #24 pack-years, 1.7 (95% CI=1.2–
2.4) for adenocarcinoma and .24 pack-years, 3.7 (95% CI=3.8–
7.6) for other histologies (squamous cell, large cell, and small cell
carcinoma) and #24 pack-years, 1.6 (95% CI=1.1–2.2) for other
histologies and .24 pack-years (LRT p-value =0.02). The
associations of emphysema, COPD, and asthma and risk of
adenocarcinoma and other histologies varied little by high or low
pack-years (LRT p-values =0.4, 0.2, and 0.2, respectively).
Discussion
In this large study of chronic obstructive pulmonary disease
(COPD) and lung cancer, we found that history of chronic
bronchitis, emphysema, and COPD were associated with
increased risk of lung cancer. The risk in patients with both
chronic bronchitis and emphysema was similar to that in patients
with only chronic bronchitis or emphysema. Previous asthma was
associated with decreased risk of lung cancer in males. Additional
adjustment for smoking beyond pack-years and smoking intensity
did not materially change these results.
While there is strong and compelling evidence for associations
between COPD and lung cancer [14–16,31], some have argued
that this association may be largely due to smoking, even after
adjustment [32]. However, several lines of evidence suggest that
the association between COPD and lung cancer may not be
entirely due to smoking. Family history of chronic bronchitis and
emphysema are associated with increased risk of lung cancer [33].
In addition, COPD is associated with lung cancer in never-
smokers [31]. A recent study estimated that COPD accounts for
10% of lung cancer cases among never smokers and 12% among
Table 1. Distribution of cases and controls in the
Environment And Genetics in Lung cancer Etiology study who
provided data on chronic bronchitis, emphysema, or asthma
diagnosed at least one year prior to study entry.
Cases Controls
Characteristic Sub-category N % N %
Study age
,60 420 21.7 543 25.8
60–,65 339 17.5 370 17.6
65–,70 429 22.2 486 23.1
.=70 746 38.6 709 33.6
Gender
Male 1528 79.0 1610 76.4
Female 406 21.0 498 23.6
Education*
None 112 5.8 90 4.3
Elementary 748 38.7 570 27.0
Middle school 554 28.7 612 29.0
High school 418 21.6 574 27.2
University 101 5.2 262 12.4
Marital status
Married/cohabitating 1491 77.1 1741 82.6
Not married/
cohabitating
443 22.9 367 17.4
Smoking status*
Never 133 6.9 678 32.2
Former 833 43.1 905 43.0
Current 968 50.1 524 24.9
Chronic bronchitis*
No 1466 77.7 1943 93.1
Yes 421 22.3 144 6.9
Emphysema*
No 1699 89.3 2038 97.0
Yes 203 10.7 62 3.0
COPD*
{
No 1372 72.9 1908 91.6
Yes 509 27.1 174 8.4
Asthma*
No 1836 95.9 2005 95.3
Yes 78 4.1 99 4.7
*Does not sum to total due to missing values.
{COPD=chronic obstructive pulmonary disease (chronic bronchitis and/or
emphysema).
doi:10.1371/journal.pone.0007380.t001
COPD and Lung Cancer
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cinoma, which is more common among non-smokers, particularly
women [4], COPD remained strongly associated with lung cancer.
In addition, the association between chronic bronchitis and lung
cancer was stronger among smokers with lower pack-years,
smoking intensity, and smoking duration. The stronger association
Table 2. Associations of lung cancer with lung disease diagnosed at least one year prior in the Environment And Genetics in Lung
cancer Etiology case-control study.
Lung disease Sub-category Minimally Adjusted OR (95% CI)* Fully Adjusted OR (95% CI)
{
Chronic bronchitis
No 1.0 1.0
Yes 3.8 (3.1–4.7) 2.0 (1.6–2.5)
Emphysema
No 1.0 1.0
Yes 3.8 (2.8–5.1) 1.9 (1.4–2.7)
COPD
{
No 1.0 1.0
Yes 4.1 (3.4–4.9) 2.5 (2.0–3.1)
Asthma in males
No 1.0 1.0
Yes 0.77 (0.54–1.1) 0.48 (0.30–0.78)
Asthma in females
No 1.0 1.0
Yes 01.1 (0.64–2.0) 1.1 (0.57–2.3)
*OR=odds ratio, CI=confidence interval. Adjusted for study age, sex, and region.
{OR=odds ratio, CI=confidence interval. Adjusted for study age, sex, region, pack-years, amount of cigarette smoking (average packs/day), bronchitis (unless main
effect or COPD), emphysema (unless main effect or COPD), and pneumonia.
{COPD=chronic obstructive pulmonary disease (chronic bronchitis and/or emphysema).
doi:10.1371/journal.pone.0007380.t002
Table 3. Associations of lung cancer with lung disease diagnosed at least one year prior and lung cancer in the Environment And
Genetics in Lung cancer Etiology case-control study, stratified by smoking status.
Lung Disease Sub-category Never Former Current LRT
{ p-value
Chronic bronchitis
Cases, N yes/total (%) 7/131 (5.3) 185/813 (22.8) 229/943 (24.3) 0.6
Controls, N yes/total (%) 20/673 (3.0) 70/895 (7.8) 54/519 (10.4)
OR (95% CI)* 2.0 (0.75–5.5) 2.1 (1.5–2.9) 1.8 (1.2–2.5)
Emphysema
Cases, N yes/total (%) 2/131 (1.5) 96/819 (11.7) 105/952 (11.0) 0.3
Controls, N yes/total (%) 13/677 (1.9) 32/900 (3.6) 17/522 (3.3)
OR (95% CI)* 0.69 (0.14–3.5) 2.0 (1.3–3.3) 2.2 (1.2–3.9)
COPD
{
Cases, N yes/total (%) 8/130 (6.2) 224/808 (27.7) 277/943 (29.4) 0.4
Controls, N yes/total (%) 29/672 (4.3) 84/893 (9.4) 61/517 (11.8)
OR (95% CI)* 1.5 (0.60–3.6) 2.7 (2.0–3.7) 2.3 (1.7–3.2)
Asthma in males
I
Cases, N yes/total (%) 0/29 (0.0) 28/714 (3.9) 27/770 (3.5) 0.3
Controls, N yes/total (%) 22/395 (5.6) 39/794 (4.9) 12/418 (2.9)
OR (95% CI)* 0 0.44 (0.24–0.82) 0.70 (0.31–1.6)
*OR=odds ratio, CI=confidence interval. Adjusted for study age, sex, region, bronchitis (unless main effect or COPD), emphysema (unless main effect or COPD) and
pneumonia for never smokers and also pack-years and amount of cigarette smoking (average packs/day) for smokers.
{COPD=chronic obstructive pulmonary disease (chronic bronchitis and/or emphysema).
{LRT=likelihood ratio test.
IOR=0.76 (95% CI=0.26–2.2) in female never smokers and 1.7 (95% CI=0.59–5.1) in female ever smokers, LRT p-value =0.2.
doi:10.1371/journal.pone.0007380.t003
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smoking share some molecular features, possibly involving
inflammation. We can speculate that among lighter smokers both
chronic bronchitis and smoking strongly contribute, while at
heavier smoking levels some ‘‘saturation’’ occurs so that the
contribution of chronic bronchitis to lung cancer appears less
prominent. To fully evaluate these factors in concert with
molecular and genetic markers (which for example, may assess
inflammation and associated genes), larger studies in consortial
settings will be required. Taken together, our data suggest that
COPD contributes independently to lung cancer risk and are
concordant with other evidence that some proportion of COPD
cases develop lung cancer because of COPD itself, rather than
because of its association with smoking. One potential mechanism
is lung infections leading to inflammation, chronic immune
stimulation [35], COPD exacerbation, and accelerated lung
function decline [36]. Although our data suggest that COPD
may contribute independently to the risk of lung cancer, the
proportion of never-smoking cases in EAGLE was small,
underscoring the need for additional analyses among never
smokers.
Previous studies have not found consistent patterns in the
association of chronic bronchitis and emphysema with lung cancer
by latency [37–40]. Our finding that chronic bronchitis was most
strongly associated with lung cancer among people who were
diagnosed with chronic bronchitis more than 15 years prior to
diagnosis of lung cancer is noteworthy because it rules out the
possibility that the association with chronic bronchitis is due to
reverse causality, i.e., the diagnosis of chronic bronchitis due to
underlying lung cancer. Moreover, it suggests that chronic
bronchitis may act in an early stage of lung carcinogenesis.
We found that asthma was associated with a decreased risk of lung
cancer in males. While a previous meta-analysis found a modest
increased risk for lung cancer associated with asthma, the magnitude
of the risk ratios varied widely by study [41]. Most previous studies of
asthma and lung cancer did not account for negative confounding by
chronic bronchitis and emphysema. Of two that did, one found an
OR of 1.5 (95% CI=1.0–2.2) for asthmaand risk of lung cancer after
adjusting for chronic bronchitis and emphysema [37]. This study was
conducted in nonsmoking women, however, and is therefore not
comparableto ours since we found an inverse association only among
males. The other study was conducted in males and females and
found an OR of 1.1 (95% CI=1.0–1.2) for asthma only and 0.73
(95% CI=0.65–0.83) for both asthma and hay fever and lung cancer
mortality. Our results were unaffected by adjustment for additional
smoking variables, including environmental tobacco smoke, and
support several studies that found inverse associations with asthma,
eczema, and hay fever [15,40,42–44]. Although previous studies of
the time from diagnosis of asthma to diagnosis of lung cancer have
been inconsistent [37–40], we found that asthma was consistently
inversely associated whether it was diagnosed within 5 years or more
than 15 years prior to lung cancer.
Several potential explanations have been hypothesized for an
inverse association between asthma and lung cancer [45].
Asthmatics might avoid smoking and other deleterious exposures
that could trigger their asthma symptoms. Avoidance of such
exposures may subsequently decrease their risk of lung cancer.
However, we carefully adjusted for smoking and saw no consistent
trends for asthma by smoking status. Often asthmatics are
administered allergy medications (antihistamines, decongestants,
corticosteroids, bronchodilators, antibiotics, etc.) over long periods
of time due to the chronic nature of asthma. Although the potential
impact of these medications on lung carcinogenesis is unclear,
antibiotics, for example, might eliminate lung pathogens postulated
to increase risk of lung cancer, such as Chlamydia pneumonia [46].
Finally, the ‘‘immunesurveillance hypothesis’’ suggests that asthma
may stimulate the immune system suchthat it is better able to detect
and destroy cancer cells [45]. That the inverse association is limited
Table 4. Associations of lung cancer with lung disease diagnosed at least one year prior and lung cancer in the Environment And
Genetics in Lung cancer Etiology case-control study restricted to current smokers (968 cases, 524 controls) and stratified by
smoking status (tertiles among controls).
Chronic bronchitis Emphysema COPD
{ Asthma in males
Smoking Variable Tertile OR (95% CI)*
LRT
{
p-value OR (95% CI)*
LRT
{
p-value OR (95% CI)*
LRT
{
p-value OR (95% CI)*
LRT
{
p-value
Pack-years
,14.4 5.0 (1.5–16.4) ,0.001 3.5 (0.26–45.4) 0.05 5.0 (1.7–15.2) ,0.001 0.26 (0.02–4.2) 0.2
14.4–,34.5 2.1 (1.1–4.1) 1.5 (0.52–4.0) 2.4 (1.3–4.3) 1.5 (0.14–17.2)
.=34.5 1.3 (0.81–2.0) 2.7 (1.3–5.6) 1.9 (1.2–3.0) 0.70 (0.25–1.9)
Intensity
(average ,0.5 7.1 (2.0–25.5) ,0.001 2.5 (0.44–14.7) 0.07 5.6 (1.9–16.4) ,0.001 1.2 (0.10–13.2) 0.3
packs/day) 0.5–,1 1.3 (0.70–2.6) 3.2 (1.0–9.8) 2.1 (1.2–3.9) 0.49 (0.05–5.3)
.=1 1.6 (0.99–2.5) 1.8 (0.88–3.7) 2.0 (1.3–3.1) 0.88 (0.32–2.4)
Duration
(years) ,26 4.5 (1.5–13.2) 0.02 2.3 (0.20–28.0) 0.8 6.2 (2.1–17.8) 0.08 0.36 (0.05–2.8) 0.5
26–,40 3.3 (1.6–6.8) 1.2 (0.39–4.0) 3.1 (1.6–6.1) 1.1 (0.16–7.5)
.=40 1.1 (0.70–1.7) 2.7 (1.4–5.5) 1.7 (1.1–2.6) 0.77 (0.26–2.3)
*OR=odds ratio, CI=confidence interval. Adjusted for study age, sex, region, bronchitis (unless main effect or COPD), emphysema (unless main effect or COPD),
pneumonia, pack-years, and amount of cigarette smoking (average packs/day).
{LRT=likelihood ratio test, using continuous smoking variables.
{COPD=chronic obstructive pulmonary disease (chronic bronchitis and/or emphysema).
doi:10.1371/journal.pone.0007380.t004
COPD and Lung Cancer
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sex-specific differences in the prevalence and severity of asthma,
possibly due to bronchial hyperresponsiveness, differential effects of
tobacco, or hormone related differences [47]. While we are unsure
why we see inverse associations in males, verification and follow-up
in other settings is desirable.
Our study has clear strengths. It is population-based and
achieved a very high participation rate among both cases and
controls. The study questionnaires were administered by inter-
viewers who underwent centralized training, ensuring that
important demographic and risk factor information (e.g., age,
smoking) was obtained as accurately and completely as possible. In
addition, quality control procedures were built into all facets of
data collection and transfer [17].
These results must also be interpreted in the light of the study’s
limitations. Despite the large initial sample size, small numbers
limited some sub-analyses (e.g., in never smokers). Given that
previous lung disease exposure was ascertained through self-
report, recall bias is possible. However, cases did not report all
previous lung diseases at a consistently higher level than controls,
as shown by the positive associations of chronic bronchitis and
emphysema with lung cancer compared to the negative association
for asthma. In addition, self report-based COPD was strongly
associated spirometry-based COPD in a subset of cases with
spirometry data, supporting a previous validation study that found
self-reported COPD sufficiently robust for accurate estimation of
relative risks [48]. While the prevalence of COPD varies notably
in the published literature, the prevalence of COPD in controls in
EAGLE (6.9%) was similar to the pooled prevalence of COPD in
Europe (7.4%) [20]. In addition, the prevalence of asthma in
EAGLE controls (4.7%) was similar to that reported in a general
population study of northern and central Italy (3.3–5.5%) [49].
This similarity suggests little potential for selection bias in EAGLE,
consistent with the careful protocol for population control accrual
in EAGLE. Although surveillance bias (i.e., increased lung cancer
diagnosis in individuals with COPD due to increased medical
investigations such as chest X-rays) is theoretically possible, the
differences in the magnitude and direction of associations for
chronic bronchitis and emphysema versus asthma and the stability
or increased strength of the findings over time, as demonstrated
through latency analysis, argue strongly against this interpretation.
The consistency of our results with the previous COPD literature
is a further indication of their validity.
In one of the largest studies of COPD and lung cancer to date,
we verified the associations of chronic bronchitis, emphysema, and
COPD with lung cancer. Our extensive analyses of these
associations by smoking status suggest that a component of the
associations is independent of smoking. This independent
association of COPD with lung cancer risk could potentially arise
from chronic inflammation. The inverse association with asthma is
consistent with some previous observations, and its restriction to
men might explain some of the inconsistency in the literature.
Further investigations in studies powered to evaluate men and
women separately are warranted.
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